Will Lilly's Zepbound make CPAP machines obsolete? Experts split STATTirzepatide Significantly Reduces Sleep Disruptions MedscapeWhy a Pair of Eli Lilly Clinical Trials Sent ResMed Stock Tumbling InvestopediaLilly's tirzepatide reduced obstructive sleep apnea (OSA) severity, with up to 51.5% of participants meeting the criteria for disease resolution | Eli Lilly and Company Investors | Eli Lilly and Company